The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Open accessAbstract
The methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is an important predictive biomarker for benefit from alkylating agent therapy in glioblastoma. Recent studies in anaplastic glioma suggest a prognostic value for MGMT methylation. Investigation of pathogenetic and epigenetic features of this intriguingly distinct behavior requires accurate MGMT classification to assess high throughput molecular databases. Promoter methylation-mediated gene silencing is strongly dependent on the location of the methylated CpGs, complicating classification. Using the HumanMethylation450 (HM-450K) BeadChip interrogating 176 CpGs annotated for the MGMT gene, with 14 located in the promoter, two distinct regions in the CpG island of the promoter were identified with high importance for gene silencing and outcome prediction. A logistic regression model (MGMT-STP27) comprising probes cg12434587 [corrected] and cg12981137 provided good classification properties and prognostic value (kappa = 0.85; log-rank p < 0.001) using a training-set of 63 glioblastomas from homogenously treated patients, for whom MGMT methylation was previously shown to be predictive for outcome based on classification by methylation-specific PCR. MGMT-STP27 was successfully validated in an independent cohort of chemo-radiotherapy-treated glioblastoma patients (n = 50; kappa = 0.88; outcome, log-rank p < 0.001). Lower prevalence of MGMT methylation among CpG island methylator phenotype (CIMP) positive tumors was found in glioblastomas from The Cancer Genome Atlas than in low grade and anaplastic glioma cohorts, while in CIMP-negative gliomas MGMT was classified as methylated in approximately 50 % regardless of tumor grade. The proposed MGMT-STP27 prediction model allows mining of datasets derived on the HM-450K or HM-27K BeadChip to explore effects of distinct epigenetic context of MGMT methylation suspected to modulate treatment resistance in different tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Model selection and multimodel inference: a practical information-theoretic approach.
Guthery, F. S., Burnham, K. P., & Anderson, D. R. (2003) · The Journal of Wildlife Management · doi:10.2307/3802723 · Cited by 41,495
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationHosmer, D. W., & Lemeshow, S. (2000) · doi:10.1002/0471722146 · Cited by 20,302
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationNelder, J. A., & Wedderburn, R. W. M. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344614 · Cited by 7,194
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Estimating regression models with unknown break‐points
Muggeo, V. M. R. (2003) · Statistics in Medicine · doi:10.1002/sim.1545 · Cited by 2,371
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Du, P., Zhang, X., Huang, C.-C., Jafari, N., Kibbe, W. A., Hou, L., & Lin, S. M. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-587 · Cited by 2,136
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Collett, D. (1991) · Springer eBooks · doi:10.1007/978-1-4899-4475-7 · Cited by 1,936
Faraway, J. J. (2005) · Cited by 1,343
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Self-citationEsteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Self-citationCpG island methylator phenotype in cancer
Issa, J.-P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1507 · Cited by 1,098
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Self-citationHegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Self-citationWick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Self-citationHegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Self-citationMGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citationMurat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
Self-citationGenome-scale analysis of aberrant DNA methylation in colorectal cancer
Hinoue, T., Weisenberger, D. J., Lange, C. P. E., Shen, H., Byun, H.-M., Van Den Berg, D., Malik, S., Pan, F., Noushmehr, H., van Dijk, C. M., et al. (2012) · Genome Research · doi:10.1101/gr.117523.110 · Cited by 601
Patefield, W. M. (1981) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.2307/2346669 · Cited by 517
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M. C., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 297
Self-citationOchs, K., & Kaina, B. (2000) · PubMed · Cited by 291
Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme
Zinn, P. O., Majadan, B., Sathyan, P., Singh, S. K., Majumder, S., Jolesz, F. A., & Colen, R. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025451 · Cited by 265
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., Taphoorn, M. J. B., Frenay, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1034 · Cited by 255
Self-citationPredictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 252
Self-citationDNA methylation in glioblastoma: impact on gene expression and clinical outcome
Etcheverry, A., Aubry, M., de Tayrac, M., Vauleon, E., Boniface, R., Guenot, F., Saikali, S., Hamlat, A., Riffaud, L., Menei, P., et al. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-701 · Cited by 223
Vlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., et al. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070169 · Cited by 197
Self-citationIdentification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Everhard, S., Tost, J., El Abdalaoui, H., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle-Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177
Nakagawachi, T., Soejima, H., Urano, T., Zhao, W., Higashimoto, K., Satoh, Y., Matsukura, S., Kudo, S., Kitajima, Y., Harada, H., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207183 · Cited by 173
Malley, D. S., Hamoudi, R., Kocialkowski, S., Pearson, D. M., Collins, V. P., & Ichimura, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0803-5 · Cited by 152
Analysis of Promoter CpG Island Hypermethylation in Cancer: Location, Location, Location!
van Vlodrop, I. J. H., Niessen, H. E. C., Derks, S., Baldewijns, M. M. L. L., Criekinge, W. V., Herman, J. G., & van Engeland, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3394 · Cited by 149
Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene
Harris, L. C., Potter, P. M., Tano, K., Shiota, S., MITRA, S. P., & Brent, T. P. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.22.6163 · Cited by 139
中川内, 哲. (2004) · Institutional Repositories DataBase (IRDB) · Cited by 138
Lambiv, W. L., Vassallo, I., Delorenzi, M., Shay, T., Diserens, A., Misra, A., Feuerstein, B. G., Murat, A., Migliavacca, E., Hamou, M., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor036 · Cited by 134
Self-citationGILBERT, M. R., Wang, M., Aldape, K., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2006 · Cited by 134
Self-citationShah, N., Lin, B., Sibenaller, Z. A., Ryken, T. C., Lee, H., Yoon, J., Rostad, S. W., & Foltz, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016146 · Cited by 112
van den Bent, M. J., Gravendeel, L. A. M., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., Teepen, J. L. J. M., Idbaïh, A., Sanson, M., Smitt, P. A. E. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1274 · Cited by 108
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
Crinière, E., Kaloshi, G., Laigle–Donadey, F., Lejeune, J., Auger, N., Benouaich‐Amiel, A., Everhard, S., Mokhtari, K., Polivka, M., Delattre, J., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9320-0 · Cited by 93
Hegi, M. E., Janzer, R.-C., Lambiv, W. L., Gorlia, T., Kouwenhoven, M. C. M., Hartmann, C. J., von Deimling, A., Martinet, D., Schmutz, N. B., Diserens, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0938-4 · Cited by 93
Self-citationSciuscio, D., Diserens, A., Dommelen, K. V., Martinet, D., Jones, G., Janzer, R.-C., Pollo, C., Hamou, M., Kaina, B., Stupp, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1931 · Cited by 84
Self-citationStupp, R., van den Bent, M. J., Erridge, S. C., Reardon, D. A., Hong, Y., Wheeler, H. T., Hegi, M. E., Perry, J., Picard, M. A., & Weller, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.tps152 · Cited by 24
Self-citationWright, K. D., & Gilbertson, R. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.020 · Cited by 11
Cited by
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationWeller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Self-citationLomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Self-citationGlioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Metadata
- Authors
- Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., Mcdonald, D. R., Lacombe, D., Stupp, R., Delorenzi, M., & Hegi, M. E.
- Venue
- Acta Neuropathologica
- Published
- 2012-07-19
- Volume
- 124
- Issue
- 4
- Pages
- 547-560
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2171418517
- Cited by
- 344
- References
- 58
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.